Man-in-Plant. At the discretion of the Government and seven calendar (7) days advance notice to the Contractor in writing from the Contracting Officer, the Government may place a man-in- plant in the Contractor's facility, who shall be subject to the Contractor's policies and procedures regarding security and facility access at all times while in the Contractor's facility. As determined by federal law, no Government representative shall publish, divulge, disclose, or make known in any manner, or to any extent not authorized by law, any information coming to him in the course of employment or official duties, while stationed in a contractor plant.
Man-in-Plant. WuXi Biologics agrees that, at Client’s option and sole expense, Client representatives may be present at the Manufacturing Site (including adequate temporary desk space and other reasonable resources available to these representatives at WuXi Biologics’ expense during the periods they are at the Manufacturing Site) during the Manufacturing of the Products for the purposes of inspecting, sampling, check weighing, and documenting Manufacturing of the Products and all associated records in connection therewith. Client representatives shall have reasonable access to (i) those portions of the Manufacturing Site where Product is Manufactured, subject to WuXi Biologics’ then-current SOPs; and (ii) full visibility and transparency to the activities being undertaken with respect to the Manufacture of Product. Any Client employees who are present at the Manufacturing Site shall comply with WuXi Biologics’ site regulations and rules. The Client representative, if present, does not have responsibility for the supervision of WuXi Biologics’ personnel or the Manufacturing of the Products. However, if at any time the Client representative objectively and reasonably determines that WuXi Biologics is operating in a manner not compliant with the terms of this Agreement or Applicable Laws or cGMP, he/she may recommend that WuXi Biologics cease operations until such condition is remedied or otherwise recommend a modification to such operations to overcome such concern; provided that, in the event that WuXi Biologics does not follow and adhere to such recommendation, then WuXi Biologics shall indemnify the Client pursuant to Section 18.1 from any Third Party Claims occurring or resulting from such failure to follow and adhere to such recommendation.
Man-in-Plant. With [**] days advanced notice to the Contractor, in writing from the Contracting Officer, the Government may place one (1) man-in-plant in the Contractor’s facility. The individual shall be subject to the Contractor’s policies and procedures regarding security and facility access at all times while in the Contractor’s facility.
Man-in-Plant. Asterias may designate a Man-In-Plant who will be present in the Facility during the testing and production phases of the Manufacturing Process in consideration of a fee based on the specific Services the Man-In-Plant will participate in, but not to exceed [***] per Man-In-Plant.
Man-in-Plant. At Asterias’s discretion, and in consideration of the fee payable pursuant to the applicable SOW (in all cases not to exceed [***]), Asterias may designate an individual (the “Man-In-Plant”) who will be present in the Facility during the testing and production phases of the Manufacturing Process.
Man-in-Plant. With five days advance notice to the Subcontractor in writing from AstraZeneca, the Government or AstraZeneca may place a man-in-plant in the Subcontractor’s facility, who shall be subject to the Subcontractor’s policies and procedures regarding security and facility access at all times while in the Subcontractor’s facility. No Government representative shall publish, divulge, disclose, or make known in any manner, or to any extent not authorized by law, any information coming to him in the course of employment or official duties, while stationed in a Subcontractor plant.
Man-in-Plant. With five days advance notice to the Subcontractor in writing from AstraZeneca, the Government or AstraZeneca may place a man-in-plant in the Subcontractor’s facility, who shall be subject to the Subcontractor’s policies and procedures regarding security and facility access at all times while in the Subcontractor’s facility. No Government representative shall publish, divulge, disclose, or make known in any manner, or to any extent not authorized by law, any information coming to him in the course of employment or official duties, while stationed in a Subcontractor plant.
1) Supplies and Services used or purchased pursuant to the contract. Includes subcontracts, professional or consultant costs, lab supplies, contract-specific security costs, manufacturing and production costs, shipping materials, shipping costs, etc. Supplies and services will be reimbursed conditionally on those costs being reasonable, allocable and allowable.
2) Materials used in development or placed in the production process for use on the contract. Material costs will be reimbursed conditionally on those costs being reasonable, allocable and allowable.
3) Labor costs incurred pursuant to the contract.
a. Direct salary ceilings are capped at Executive Level II ($183,300 direct costs per year per person.)
b. If the rates are burdened, those rates are evaluated at its direct rate and the overhead/indirect rate(s). The rates will be authorized if reasonable, allocable and allowable to this contract.
4) Legal costs incurred as a direct result of a specific term or condition of a Federal contract; or as a result of compliance with specific written direction of the contracting officer.
5) Service and warranty costs necessary for the proper performance of the agreement. Service and warranty costs include those arising from fulfillment of any contractual obligation of a contractor to provide services such as installation, training, correcting defects in the products, replacing defective parts, and making refunds in the case of inadequate performance. When not inconsistent with the terms of the contract, service and warranty costs are allowable. However, care should be exercised to avoid duplication of the allowance as an element of both estimated product cost and risk.
